Dairy producers have a new management option for managing anestrous cows. Zoetis announced today that Eazi-Breed™ CIDR® Cattle Insert now has a label indication for inducing estrous cycles in anestrous lactating dairy cows.
Anestrus is a cow’s failure to show signs of heat (estrus) or estrous cycles. Incidence of anestrus during the postpartum period can negatively influence fertility.
“Anestrous cows are difficult to detect and can be a significant problem for dairies, leading to delayed breeding, longer intervals to calving, longer days in milk and ultimately, lower profits.” said Jerry Olson, DVM, Dairy Technical Services, Zoetis. “When cows fail to cycle, it can be an expensive problem.”
Today, the prevalence of anestrous cows in U.S. dairy herds is estimated at 20% to more than 40%.1 Each additional day a cow is past her Voluntary Waiting Period could cost more than $3.00 per cow per day.2
“At a time of less than favorable milk prices, producers need to capitalize on all possible efficiencies on the dairy,” said Dr. Olson. “When cows spend more time in early lactation, they produce more milk. Managing cows for successful production requires a solid reproduction program to shorten calving intervals, which is the key to keeping cows in peak milk production.”
Study: Eazi-Breed™ CIDR® significantly improved estrous cycling
Eazi-Breed CIDR helps improve the effectiveness of reproduction programs by tightening estrous synchronization so groups of cows and heifers begin cycling, come into heat sooner and can be bred in a narrower window.
In a multisite field study, the efficacy and safety of Eazi-Breed CIDR was evaluated in postpartum cows at nine commercial dairies:3 Of the enrolled cows:
•426 anestrous cows received Eazi-Breed CIDR for seven days
•430 anestrous cows received no treatment
During a 42-day observation period, cows that received Eazi-Breed CIDR showed a 37.5% relative improvement in the rate of estrous cycling induction, a significant improvement (P < 0.0001) over controls. Additionally, of those inseminated in the Eazi-Breed CIDR group during days 1 to 21, 78.3% were inseminated on the second and third day following removal of Eazi-Breed CIDR.
Repro success requires team effort
“At Zoetis, we understand the changing needs of today’s dairy producers and veterinarians.” said Dr. Olson. “A successful dairy reproduction program requires a team effort.”
For more than 30 years, Zoetis has been delivering innovations to help producers and veterinarians improve reproductive programs, including these estrous synchronization product approvals:
•Fixed-time artificial insemination with FACTREL® Injection (gonadorelin injection) and LUTALYSE® Injection (dinoprost injection)
FACTREL is approved by the Food and Drug Administration (FDA) for use with LUTALYSE to synchronize estrous cycles for fixed-time artificial insemination (AI) in lactating dairy cows. And because it is consistent with most dairy cow breeding protocols recommended by the Dairy Cattle Reproduction Council, producers and veterinarians can tailor the program to fit the needs of their individual operations.
•Estrous synchronization with LUTALYSE and Eazi-Breed™ CIDR®
Used concurrently, LUTALYSE and Eazi-Breed CIDR improve dairy cow breeding efficiency and pregnancy success. LUTALYSE is the only prostaglandin approved by the FDA for use in synchronization protocols with Eazi-Breed CIDR.*
Learn more about the Eazi-Breed CIDR Cattle Insert, visit CIDR.com/Dairy or contact your veterinarian or Zoetis representative.
IMPORTANT SAFETY INFORMATION FOR EAZI-BREED CIDR: Avoid contact with skin by wearing protective gloves when handling Eazi-Breed CIDR inserts. Do not use in heifers of insufficient size or age for breeding or in cattle with abnormal, immature, or infected genital tracts. Do not use inserts more than once.
IMPORTANT SAFETY INFORMATION FOR FACTREL INJECTION: FACTREL Injection is for use in cattle only. Please see full Prescribing Information here.
IMPORTANT SAFETY INFORMATION FOR LUTALYSE INJECTION: Women of childbearing age and persons with respiratory problems should exercise extreme caution when handling LUTALYSE. LUTALYSE is readily absorbed through the skin and may cause abortion and/or bronchiospasms, therefore spillage on the skin should be washed off immediately with soap and water. Aseptic technique should be used to reduce the possibility of post-injection clostridial infections. Do not administer LUTALYSE in pregnant cattle unless cessation of pregnancy is desired. See full Prescribing Information here.
About Zoetis
Zoetis (zō-EH-tis) is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 60 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products and genetic tests and supported by a range of services. In 2014, the company generated annual revenue of $4.8 billion. With approximately 10,000 employees worldwide at the beginning of 2015, Zoetis serves veterinarians, livestock producers and people who raise and care for farm and companion animals with sales of its products in 120 countries. For more information, visit www.zoetisUS.com.
For Further Information,Contact:
Jillian Spector
Zoetis
973-443-2847
jillian.spector@zoetis.com
Bader Rutter
262-938-5577
khopkins@bader-rutter.com
